[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567506":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":25,"responsibleParty":36,"collaborators":25,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":40,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":25,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":60,"whyStopped":25,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":68,"locationsCount":25},{"fullName":5,"class":6},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"NALIRINOX combined with PD-1 synchronous sequential SBRT group","EXPERIMENTAL","Nal-IRI+Oxaliplatin+5- FU +PD-1, these drugs are given on d1, d15, 28 days as one cycle, SBRT is performed during the third and fourth cycle.",[13],"Drug: Nal-lRl+Oxaliplain+5- FU +PD 1",{"label":15,"type":10,"description":16,"interventionNames":17},"NALIRIFOX group","Nal-IRI+Oxaliplatin+5- FU, these drugs are given on d1, d15, 28 days as one cycle.",[18],"Drug: Nal-lRl+Oxaliplain+5- FU",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Nal-lRl+Oxaliplain+5- FU +PD 1","Nal-lRl+Oxaliplatin+5- FU +PD-1, these drugs are given on d1, d15, 28 days as one cycle, SBRT is performed during the third and fourth cycle.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Nal-lRl+Oxaliplain+5- FU","Nal-lRl+Oxaliplatin+5- FU, these drugs are given on d1, d15, 28 days as one cycle.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Qiu Yudong M.D., Ph.D","CONTACT","+86-025-83106666","yudongqiu510@163.com",{"type":37,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100567506","phase-2-nalirifox-combined-with-pd-1-sequential-radiotherapy-versus-nalirifox-as-conversion-therapy-of-locally-advanced-pancreatic-cancer-100567506",false,"NCT06669078","NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer","A Prospective, Open, Randomized Controlled, Multicenter, Exploratory Clinical Study of NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX for Conversion Therapy for Locally Advanced Pancreatic Cancer","NALIRIFOX","Inclusion Criteria:\n\n1. Histologically or cytologically confi rmed pancreatic cancer;\n2. ECOG performance no more than 1;\n3. Radiographically assessed as locally advanced pancreatic cancer according ;\n4. No previous anti-tumor therapy;\n5. Able and willing to provide a written informed consent.\n\nExclusion Criteria:\n\n1. Prior anti-tumor therapy of any kind;\n2. Known to be symptomatic central nervous system metastasis and\u002For cancerous meningitis.\n3. Patients with autoimmune disease or immune deficiency who are treated with immuno-suppressive drugs;\n4. Patients with bleeding tendency;\n5. Pregnant or lactating women.","ALL","18 Years","75 Years",{"count":50,"type":51},120,"ESTIMATED","INTERVENTIONAL",[54],"PHASE2","The purpose of the prospective, open, randomized controlled, multicenter, exploratory clinical study is to evaluate efficacy and safety of NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX for Conversion Therapy for Locally Advanced Pancreatic Cancer",[57],"Locally Advanced Pancreatic Cancer",[44,59,57],"Conversion Therapy","NOT_YET_RECRUITING","2024-10-30",{"date":63,"type":64},"2024-11-01","ACTUAL",{"date":61,"type":51},{"date":67,"type":51},"2027-10-15",{"name":5,"class":6}]